Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The pathologist's view point. Part II --aggressive lymphomas.

S A Pileri1, S Ascani, E Sabattini

  • 1Service of Pathologic Anatomy and Hematopathology, Institute of Hematology and Oncology L. & A. Seràgnoli, Bologna University, Policlinico S. Orsola, Italy. pileri@almadns.unibo.it

Haematologica
|December 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia.

EJHaem·2023
Same author

EBV persistence in gastric cancer cases conventionally classified as EBER-ISH negative.

Infectious agents and cancer·2022
Same author

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.

ESMO open·2021
Same author

Correction to: A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit.

Virchows Archiv : an international journal of pathology·2019
Same author

A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit : A position paper from the Italian Group of Haematopathology (G.I.E.).

Virchows Archiv : an international journal of pathology·2019
Same author

Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

The REAL/WHO classification aids understanding and treating aggressive lymphomas. This framework facilitates tailored therapies for malignant lymphomas by integrating pathology and clinical insights.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • The REAL/WHO classification provides a novel framework for understanding and managing malignant lymphomas.
  • Focuses on key features of aggressive B-cell and T-cell lymphomas.
  • Aims to improve communication between pathologists and clinicians.

Purpose of the Study:

  • To elucidate the critical features of aggressive B- and T-cell lymphomas within the REAL/WHO classification.
  • To foster collaboration between pathology and clinical practice for improved lymphoma management.
  • To present updated diagnostic guidelines and identify future research directions.

Main Methods:

  • Comprehensive literature review of lymphoma entities.
  • Analysis based on authors' extensive experience with over 20,000 lymphoid tumors spanning 20 years.

Related Experiment Videos

  • Integration of data from novel diagnostic markers.

    • Main Results:

    • Identification and discussion of diagnostic guidelines for lymphomas.
    • Highlights areas for future clinico-pathologic research.
    • Presents findings from novel marker applications in lymphoma diagnosis.

    Conclusions:

    • Current understanding and classification of malignant lymphomas enable the development of targeted therapies.
    • The REAL/WHO classification is instrumental in advancing personalized treatment strategies.
    • Enhanced clinico-pathologic correlation is crucial for optimizing lymphoma care.